Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn’s disease in children: REACH open-label extension
Jeffrey S. Hyams(Connecticut Children's Medical Center), Robert N. Baldassano(Children's Hospital of Philadelphia), George D. Ferry(Baylor College of Medicine), G. Veereman‐Wauters(Semmelweis University), Yinghua Lang, Marion Blank(Janssen (United States)), Anne M. Griffiths(University of Toronto), Stanley A. Cohen(Troy Gastroenterology), Harland S. Winter(Harvard University), James Markowitz(Philadelphia University), Wallace Crandall, Subra Kugathasan(Emory University), Jewel Johanns(Janssen (United States)), Thomas D. Walters(University of Toronto)
Cited by 109
Related Papers
Human gut microbiome viewed across age and geography
|Nature|2012|7.9k
Linking Long-Term Dietary Patterns with Gut Microbial Enterotypes
|Science|2011|6.6k
The Treatment-Naive Microbiome in New-Onset Crohn’s Disease
|Cell Host & Microbe|2014|3.3k